文献速递慢阻肺呼吸危重症与机械通气

COPD患者无创通气医保准入优化:多学会技术专家小组报告

Optimal NIV Medicare Access Promotion: Patients With COPD: A Technical Expert Panel Report From the American College of Chest Physicians, the American Association for Respiratory Care, the American Academy of Sleep Medicine, and the American Thoracic Society.
PubMed 文献 · Chest · 2021-07-30

本文汇总美国胸科医师学会、美国呼吸治疗学会、美国睡眠医学会和美国胸科学会COPD技术专家小组的工作,指出现行覆盖障碍主要在于侧重氧合而非通气的诊断要求及获取带备用频率双水平设备困难。小组基于随机对照试验的死亡率获益证据及ATS/ERS指南,提出移除夜间血氧监测要求、允许使用带备用频率双水平设备起始治疗、对积极管理患者延长依从性达标时间等关键建议。

要点

  • 现行医保覆盖障碍包括侧重氧合的诊断要求和获取带备用频率双水平设备困难。
  • 建议移除夜间血氧监测要求,允许使用带备用频率双水平设备起始治疗。
  • 对积极管理患者延长依从性达标时间至第二个90天试验期。

核心结论

  • 为COPD患者优化无创通气准入,应移除夜间血氧监测要求、允许使用带备用频率双水平设备起始治疗,并延长依从性达标时间。

研究设计与样本

  • 美国胸科医师学会、美国呼吸治疗学会、美国睡眠医学会和美国胸科学会联合组建的COPD技术专家小组工作报告。

主要发现

  • 当前最紧迫的覆盖障碍是侧重氧合而非通气的繁重诊断要求,以及获取带备用频率双水平设备困难。
  • 许多COPD患者因此有时被处方家用呼吸机。
  • 随机对照试验证据提示带备用频率双水平正压通气具有死亡率获益。

关键数值与推荐

  • 建议移除夜间血氧监测测试的必要性。
  • 建议允许使用带备用频率能力的双水平设备起始治疗。
  • 建议对积极管理患者增加依从性达标时间,即第二个90天试验期。
  • 纳入基于医学必要的明确指南,用于需要起始或切换至家用呼吸机的患者。

临床怎么用

  • 采纳建议可为合适COPD患者及时提供合适设备。
  • 强调在起始和维持家用无创通气期间提供充分临床支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This document summarizes the work of the COPD Technical Expert Panel working group. For patients with COPD, the most pressing current coverage barriers identified were onerous diagnostic requirements focused on oxygenation (rather than ventilation) and difficulty obtaining bilevel devices with backup rate capabilities. Because of these difficulties, many patients with COPD were instead sometimes prescribed home mechanical ventilators. Critical evidence supports changes to current policies, including randomized controlled trial evidence suggesting a mortality benefit from bilevel positive airway pressure with backup rate and updated clinical practice guidelines from the American Thoracic Society as well as the European Respiratory Society. To achieve optimal access to noninvasive ventilation for patients with COPD, we make the following key recommendations: (1) removal of the need for overnight oximetry testing; (2) the ability to initiate therapy using bilevel devices with backup rate capability; and (3) increased duration of time to meet adherence criteria (ie, a second 90-day trial period) in those patients actively engaged in their care. Clear guidelines based on medical necessity are also included for patients who require initiation of or switch to a home mechanical ventilator. Adoption of these proposed recommendations would result in the right device, for the right type of patient with COPD, at the right time. Finally, we emphasize the need for adequate clinical support during initiation and maintenance of home noninvasive ventilation in such patients.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Hill NS, Criner GJ, Branson RD, et al. Optimal NIV Medicare Access Promotion: Patients With COPD: A Technical Expert Panel Report From the American College of Chest Physicians, the American Association for Respiratory Care, the American Academy of Sleep Medicine, and the American Thoracic Society. Chest. 2021. PMID: 34339684. doi:10.1016/j.chest.2021.06.082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。